Clinical Trial Update: Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing nasal inhalation of dornase alfa (Pulmozyme) in cystic fibrosis patients with chronic rhinosinusitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Rhinosinusitis

Drugs mentioned

• Pulmozyme (dornase alfa)

Snippet

Sponsor: University of Jena | Conditions: Cystic Fibrosis, Chronic Rhinosinusitis | Phase 3 | Status: COMPLETED